Detalhe da pesquisa
1.
A randomized clinical trial of the efficacy and safety of sitagliptin as initial oral therapy in youth with type 2 diabetes.
Pediatr Diabetes
; 23(2): 173-182, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34779087
2.
Efficacy and safety of the addition of sitagliptin to treatment of youth with type 2 diabetes and inadequate glycemic control on metformin without or with insulin.
Pediatr Diabetes
; 23(2): 183-193, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34779103
3.
Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
Diabetes Obes Metab
; 21(4): 781-790, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30393950
4.
Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV).
Am Heart J
; 206: 11-23, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30290289
5.
Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.
Diabetes Obes Metab
; 20(5): 1111-1120, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29266675
6.
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
Diabetes Obes Metab
; 20(9): 2220-2228, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29766635
7.
Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo-controlled randomized study.
Diabetes Obes Metab
; 20(3): 530-540, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28921862
8.
Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open-label clinical trial.
Diabetes Obes Metab
; 20(9): 2229-2237, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29761615
9.
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
Diabetes Obes Metab
; 19(5): 721-728, 2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28116776
10.
Control-based imputation for sensitivity analyses in informative censoring for recurrent event data.
Pharm Stat
; 16(6): 424-432, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28834175
11.
Robust analyzes for longitudinal clinical trials with missing and non-normal continuous outcomes.
Stat Theory Relat Fields
; 8(1): 1-14, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38800501
12.
Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial.
Am J Kidney Dis
; 61(4): 579-87, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23352379
13.
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis.
Cardiovasc Diabetol
; 12: 3, 2013 Jan 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-23286208
14.
Efficient Multiple Imputation for Sensitivity Analysis of Recurrent Events Data with Informative Censoring.
Stat Biopharm Res
; 14(2): 153-161, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35601027
15.
A course for clinical trial personnel in clinical study designs, randomization, allocation schedules, and interactive response systems.
Pharm Stat
; 10(2): 175-82, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-20967893
16.
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes.
BMC Endocr Disord
; 10: 7, 2010 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-20412573
17.
How 4 Companies Became One: Co-development Under an Outsourced Model With Focus on Phase 3 Analysis and Reporting Deliverables.
Ther Innov Regul Sci
; 53(3): 301-306, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29911403
18.
Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Curr Med Res Opin
; 35(8): 1335-1343, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30760125
19.
Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study.
Diabetes Ther
; 9(1): 193-207, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29282633
20.
Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study.
Diabetes Ther
; 9(1): 253-268, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29313282